Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$7.90 USD
+0.04 (0.51%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $7.89 -0.01 (-0.13%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OTLK 7.90 +0.04(0.51%)
Will OTLK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OTLK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OTLK
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
OTLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
Other News for OTLK
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
3 Undervalued Gems Set to Soar 1,000% by 2026
Outlook Therapeutics management to meet virtually with BTIG
Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
Outlook Therapeutics: Worth A Good Strong Look After CRL